论文部分内容阅读
目的 :观察NVB、Vp - 16、CDDP联合应用治疗非小细胞肺癌的临床疗效和毒副作用。方法 :1997年 3月至1998年 3月对 2 6例经病理学和临床检查证实为Ⅲ -Ⅳ期非小细胞肺癌患者应用NVB 2 5mg/m2 ,第 1、8天静滴 +Vp - 1610 0mg/m2 ,第 1至 3天静滴 +CDDP 10 0mg/m2 ,第 1天静滴 ,每 2 1天为 1周期 ,共 2周期的联合化疗方案 ,对化疗后结果进行分析。结果 :CR 2例 ,PR 12例 ,无PD ,有效率为 5 3 85 % (14 / 2 6 )。毒副反应 :血液学毒性中WBC减少至 4级为 10 0 % ,血小板减少至 3～ 4级为 2 3 0 8% ,非血液学毒性中脱发为 6 1 5 4 % ,肢痛为 30 77% ,口腔粘膜溃疡为 38 4 6 % ,便秘为2 6 92 % ,周围神经毒性为 3 84 % ,静脉炎为 2 3 0 8% (NVB用一般速度静注静脉炎发生率为 4 2 86 % ,快速滴注为15 79% )。结论 :NVB +CDDP +Vp - 16治疗非小细胞肺癌有较高的疗效 ,但血液学毒性较为严重 ,静脉炎可用快速滴注方法预防
Objective : To observe the clinical efficacy and toxic side effects of NVB, Vp-16, CDDP combined with non-small cell lung cancer. METHODS: From March 1997 to March 1998, 26 patients with stage III-IV non-small-cell lung cancer confirmed by pathology and clinical examination were treated with NVB 25 mg/m2, intravenous infusion on days 1 and 8, and +Vp-1610. 0mg/m2, 1st to 3rd days of intravenous infusion + CDDP 100mg/m2, intravenous infusion on the first day, 1 cycle every 21 days, a total of 2 cycles of combined chemotherapy regimen, analysis of the results after chemotherapy. Results: There were 2 CR patients, 12 PR patients, and no PD. The effective rate was 5 3 85% (14/26). Toxic side effects: WBC reduced to 40% in hematologic toxicity, 100% in thrombocytopenia, 2-30% in thrombocytopenia, 6% in non-hematologic toxicity, and 30. % , Oral mucosal ulcers were 38 4 6%, Constipation was 266 2%, Peripheral neurotoxicity was 384 %, Phlebitis was 23% (average rate of NVB intravenous phlebitis was 4 286 % Rapid infusion of 15 79%). Conclusion : NVB +CDDP +Vp - 16 has higher curative effect on non-small cell lung cancer, but hematological toxicity is more serious. Phlebitis can be prevented by rapid instillation.